Scholarly article on topic 'PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases'

PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases Academic research paper on "Veterinary science"

0
0
Share paper
Academic journal
Pediatr Rheumatol
OECD Field of science
Keywords
{""}

Academic research paper on topic "PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases"

Kostik et al. Pediatric Rheumatology 2013, 11 (Suppl 2):P166

http://www.ped-rheum.com/content/11/S2/P166 * % PEDIATRIC

RHEUMATOLOGY

POSTER PRESENTATION Open Access

PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases

MM Kostik1*, NN Abramova2, LS Snegireva1, LI Vasykina3, MF Dubko1, VV Masalova1, TL Kornishina1, TS Likhacheva1 , IA Chikova1, NI Glebova1, NV Buchinskaya1, OV Kalashnikova1, VG Chasnyk1

From 20th Pediatric Rheumatology European Society (PReS) Congress Ljubljana, Slovenia. 25-29 September 2013

Introduction

Macrophage activation syndrome (MAS) - is a severe life-threatening hematological condition, complicated different rheumatic diseases. MAS is characterized by uncontrolled proliferation of T cells and macrophages, associated with decreased natural killer (NK) cells and cytotoxic T cell function due to mutations in perforin gene.

Objectives

The aim of our study was to evaluate early predictors associated with fatal outcomes in pediatric rheumatic disease. These clinical and biomarkers can be useful in the measurement of severity MAS.

Methods

We have performed retrospective study. Medical charts of children with definite MAS who were admitted to our rheumatology department in 2005-2013 were reviewed. We utilized the A.Ravelli criteria (2002) for detecting MAS. We used the main characteristic clinical and labora-torial markers of MAS only at the moment of MAS confirmation (± 3 days). The patients who developed MAS in the terminal study (irreversible polyorganic damage) were excluded. We evaluated demographic data, data related to MAS. Also we calculated cutoff points for fatal outcomes (ROC-analysis), performed analysis of sensitivity and specificity and identified predictors with Log-Rank analysis and Kaplan-Meier survival curves.

1Hospital Pediatry, Saint-Petersburg, Russian Federation Full list of author information is available at the end of the article

Ç ^ Bio Med Central

Results

23 patients (9 boys and 14 girls) with SLE (n = 2), AAV (n = 2), SJIA (n = 17) and virus-associated HLH (n = 2) were included. Median age of MAS was 7.4 years (range:1.5 mo-16.8 y), median time between disease onset and MAS onset 11,4 mo (range:0.4-93.6 mo) and median duration of MAS episode 68 days (range:11-336 days). Fatal outcome was in 4 patients (2 SLE, 1 AAV, 1SJIA).

The main predictors of fatal outcomes were: onset of disease>10.15 years (OR = 42.4, p = 0.004) ongoing gluco-corticosteroid treatment at the time of MAS onset (OR = 63.0, p = 0.008), flare or active course of background rheumatic disease (p = 0.015), low sodium Na<132 mmol/l (OR = 93.0, p = 0.001), no splenomegaly (p = 0.023), no lymphadenopathy (OR = 16.0, p = 0.04), hemorrhagic syndrome (OR = 31.0, p = 0.015), central nervous system involvement (p = 0.015), WBC < 2400 cells in ^l (OR = 54.0, p = 0.0001), Prothrombin < 43% (OR = 29.0, p = 0.002) and ESR >56 mm/h (OR = 39.0, p = 0.0007).

Conclusion

We detected several clinical and laboratorial markers which reflect the severity of MAS. Presence of these signs at onset of MAS can early differentiate the prognostic unfavorable group which required more intensive care.

Disclosure of interest

None declared.

Authors' details

1Hospital Pediatry, Saint-Petersburg, Russian Federation. 2ICU, Saint-Petersburg State Pediatric MedicalUniversity, Saint-Petersburg, Russian Federation. 3Immunology, FederalInstitute of Public Health «The Nikiforov's Russian Center of Emergency and Radiation Medicine», Saint-Petersburg, Russian Federation.

©2013 Kostik et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Kostik et al. Pediatric Rheumatology 2013, 11(Suppl 2):P166 http://www.ped-rheum.com/content/11/S2/P166

Page 2 of 2

Published: 5 December 2013

doi:10.1186/1546-0096-11-S2-P166

Cite this article as: Kostik et al.: PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases. Pediatric Rheumatology 2013 11 (Suppl 2):P166.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at fpntral

www.biomedcentral.com/submit v-enudi